News Release

PET/MR shows arterial CO2 as potent vasodilator for cardiac stress testing

Peer-Reviewed Publication

Society of Nuclear Medicine and Molecular Imaging

Regional Myocardial Blood Flow Response to Hypercapnia and Adenosine in the Presence of Coronary Stenosis

image: Panel A shows representative short and long-axis PET images of peak myocardial uptake of <sup>13</sup>N-ammonia during hypercapnia of PaCO<sub>2</sub> ~ 60 mmHg (CO<sub>2</sub>), standard clinical dose of adenosine (Adenosine) and at rest with PaCO<sub>2</sub> ~ 35 mmHg (Rest) in a canine with a LAD stenosis. Note the lower uptake of the radiotracer in the anterior lateral wall (lower signal in distal LAD segments, yellow arrows) under hypercapnia and adenosine. For the case in panel A, rest and stress MBF (under hypercapnia and adenosine) and corresponding MPR are shown as polar maps in panel B. These images show marked reduction in MBF and MPR in the LAD territory, which are visually evident and spatially concordant under hypercapnia and adenosine. view more 

Credit: Rohan Dharmakumar. Cedars-Sinai Medical Center

RESTON, Va. -- More than 5 million cardiac stress tests performed annually in the U.S. employ injectable forms of pharmacological stress agents--such as adenosine or one of its analogues--to dilate blood vessels in the heart. However, these drugs can have severe side effects. Using PET/MR imaging, a new international study featured in the June issue of The Journal of Nuclear Medicine demonstrates that increases in partial pressure of arterial carbon dioxide (PaCO2) can safely and efficiently widen blood vessels of the heart during stress tests to help determine heart function.

Myocardial blood flow (MBF) is critical in determining heart function. While PaCO2's effect on MBF has been studied extensively in the past, previous findings have been inconclusive due to difficulty in quickly controlling PaCO2 to limit hypercapnia (too much carbon dioxide in the blood) and uncertain measures of the outcome variable. In this new study, these issues have been addressed.

"We have overcome these technical difficulties by incorporating new technology that can accurately, precisely and rapidly control arterial blood gas levels, and we have quantified the MBF response with 13N-ammonia PET, the gold standard approach for measuring MBF, in a clinically relevant animal model," explains Rohan Dharmakumar, PhD, of the Cedars-Sinai Medical Center and University of California, Los Angeles, California. "We report for the first time that a physiologically tolerable increase in PaCO2 (~25 mmHg) amplifies MBF more than two-fold, a key feature of clinically meaningful coronary vasodilators used for cardiac stress testing."

The study included three groups of canines: (1) without coronary stenosis, (2) with non-flow limiting stenosis and (3) pre-administered caffeine (which inhibits adenosine and can affect stress-test results). In all cases, PaCO2 proved just as effective at inducing MBF as the standard dose of adenosine and performs better than adenosine in animals pre-administered with caffeine.

"This key finding opens the door to a completely new protocol for cardiac stress testing--one that has the potential to benefit numerous patients who are contraindicated for commonly used pharmacological stress agents," says Dharmakumar. "Since hypercapnia is safe and effective when its magnitude is tightly controlled, it could also empower repeat stress testing in target populations with heart disease--overcoming a limitation of current stress tests that rely on injectable pharmacological agents."


The authors of "Arterial CO2 as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing" include Hsin-Jung Yang, Damini Dey, Avinash Kali, Roya Yumul, Debiao Li, Piotr J. Slomka, Daniel S. Berman, and Rohan Dharmakumar, Cedars-Sinai Medical Center and University of California, Los Angeles, California; Jane Sykes, John Butler, Michael S. Kovacs, and Frank S. Prato, University of Western Ontario, London, Canada; Michael Klein, Olivia Sobczyk, and Joseph A. Fisher, University of Toronto, Toronto, Canada; Behzad Sharif, Ivan Cokic, Richard Tang, Antonio H. Conte, and Mourad Tighiouart, Cedars-Sinai Medical Center; Xiaoming Bi, Siemens Healthcare, Los Angeles, California; and Sotirios A. Tsaftaris, University of Edinburgh, Edinburg, UK.

This work was supported in part by a grant from the National Heart, Lung and Blood Institute at NIH (HL091989).

Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or Current and past issues of The Journal of Nuclear Medicine can be found online at

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.